Shares of GlaxoSmithKline Pharmaceuticals were trading higher in Thursday's session, with the stock marked at Rs 2,879.10, a 3.68% increase. At 10:55 am, the stock is among the top gainers on the Nifty Midcap 150 index.
GlaxoSmithKline Pharmaceuticals announced several press releases on August 25, 2025, regarding the company's foray into oncology with Jemperli and Zejula, bringing precision therapies for gynaecological cancers.
GlaxoSmithKline Pharmaceuticals has announced a final dividend of Rs 42 per share with effective date as May 30, 2025.
Financial Performance:
The following table summarizes the consolidated quarterly financial performance of GlaxoSmithKline Pharmaceuticals:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 814.65 Crore | Rs 1,010.77 Crore | Rs 949.42 Crore | Rs 974.37 Crore | Rs 805.17 Crore |
| Net Profit | Rs 182.33 Crore | Rs 252.50 Crore | Rs 229.88 Crore | Rs 262.87 Crore | Rs 205.01 Crore |
| EPS | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 |
The revenue for the quarter ending September 2024 was Rs 1,010.77 Crore, which then saw a decline in the quarter ending December 2024, with revenue at Rs 949.42 Crore. The net profit for the quarter ending March 2025 was Rs 262.87 Crore.
The following table summarizes the consolidated yearly financial performance of GlaxoSmithKline Pharmaceuticals:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,925.60 Crore | Rs 3,278.03 Crore | Rs 3,251.72 Crore | Rs 3,453.71 Crore | Rs 3,749.21 Crore |
| Net Profit | Rs 287.27 Crore | Rs 380.77 Crore | Rs 607.64 Crore | Rs 589.96 Crore | Rs 927.58 Crore |
| EPS | 31.35 | 99.29 | 36.08 | 41.14 | 54.52 |
| BVPS | 87.26 | 157.19 | 102.79 | 104.93 | 115.19 |
| ROE | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The yearly revenue has increased from Rs 2,925.60 Crore in 2021 to Rs 3,749.21 Crore in 2025. The net profit has also increased from Rs 287.27 Crore in 2021 to Rs 927.58 Crore in 2025.
Consolidated yearly income statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 3,749 | 3,453 | 3,251 | 3,278 | 2,925 |
| Other Income | 145 | 122 | 100 | 75 | 110 |
| Total Income | 3,895 | 3,576 | 3,352 | 3,353 | 3,036 |
| Total Expenditure | 2,633 | 2,758 | 2,514 | 2,572 | 2,578 |
| EBIT | 1,261 | 817 | 838 | 781 | 457 |
| Interest | 1 | 1 | 1 | 2 | 3 |
| Tax | 332 | 226 | 228 | 398 | 166 |
| Net Profit | 927 | 589 | 607 | 380 | 287 |
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 805 | 974 | 949 | 1,010 | 814 |
| Other Income | 43 | 40 | 35 | 34 | 35 |
| Total Income | 848 | 1,015 | 984 | 1,045 | 850 |
| Total Expenditure | 569 | 655 | 676 | 701 | 600 |
| EBIT | 279 | 359 | 308 | 344 | 249 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Tax | 73 | 95 | 78 | 91 | 67 |
| Net Profit | 205 | 262 | 229 | 252 | 182 |
The following table summarizes the consolidated yearly cash flow of GlaxoSmithKline Pharmaceuticals:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 1,289 | 582 | 484 | 810 | 577 |
| Investing Activities | -45 | 8 | 807 | -405 | 418 |
| Financing Activities | -769 | -561 | -1,543 | -524 | -696 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 474 | 29 | -251 | -119 | 300 |
The following table summarizes the consolidated yearly balance sheet of GlaxoSmithKline Pharmaceuticals:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 169 | 169 | 169 | 169 | 169 |
| Reserves & Surplus | 1,781 | 1,617 | 1,573 | 2,493 | 1,308 |
| Current Liabilities | 1,905 | 1,524 | 1,326 | 1,698 | 1,354 |
| Other Liabilities | 251 | 245 | 257 | 271 | 281 |
| Total Liabilities | 4,108 | 3,556 | 3,326 | 4,633 | 3,114 |
| Fixed Assets | 297 | 335 | 350 | 361 | 400 |
| Current Assets | 3,409 | 2,798 | 2,494 | 3,708 | 2,202 |
| Other Assets | 400 | 423 | 482 | 564 | 511 |
| Total Assets | 4,108 | 3,556 | 3,326 | 4,633 | 3,114 |
| Contingent Liabilities | 490 | 387 | 361 | 368 | 498 |
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 31.35 | 99.29 | 36.08 | 41.14 | 54.52 |
| Diluted Eps (Rs.) | 21.14 | 100.04 | 36.05 | 34.83 | 54.76 |
| Book Value /Share (Rs.) | 87.26 | 157.19 | 102.79 | 104.93 | 115.19 |
| Dividend/Share (Rs.) | 30.00 | 90.00 | 32.00 | 32.00 | 54.00 |
| Face Value | 10 | 10 | 10 | 10 | 10 |
| Gross Profit Margin (%) | 24.22 | 25.55 | 27.82 | 29.86 | 35.29 |
| Operating Margin (%) | 21.53 | 23.47 | 25.80 | 27.84 | 33.51 |
| Net Profit Margin (%) | 12.24 | 51.69 | 18.78 | 17.08 | 24.74 |
| Return on Networth (%) | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| ROCE (%) | 35.80 | 26.21 | 41.95 | 47.33 | 57.03 |
| Return On Assets (%) | 11.49 | 36.57 | 18.53 | 16.70 | 22.64 |
| Current Ratio (X) | 1.63 | 2.18 | 1.88 | 1.84 | 1.79 |
| Quick Ratio (X) | 1.22 | 1.87 | 1.53 | 1.49 | 1.54 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 200.69 | 419.65 | 499.36 | 573.35 | 1,007.30 |
| Asset Turnover Ratio (%) | 0.94 | 0.83 | 0.81 | 1.00 | 0.98 |
| Inventory Turnover Ratio (X) | 0.90 | 1.04 | 0.81 | 1.11 | 0.99 |
| 3 Yr CAGR Sales (%) | 0.94 | 2.37 | 0.42 | 8.65 | 6.95 |
| 3 Yr CAGR Net Profit (%) | -9.50 | -7.54 | 155.34 | 43.31 | 56.08 |
| P/E (x) | 45.96 | 16.79 | 36.72 | 47.32 | 52.83 |
| P/B (x) | 16.51 | 10.58 | 12.88 | 18.52 | 24.98 |
| EV/EBITDA (x) | 32.80 | 30.67 | 23.51 | 30.89 | 35.77 |
| P/S (x) | 8.34 | 8.59 | 6.90 | 9.53 | 13.00 |
A Moneycontrol analysis on August 28, 2025, indicated a very bearish sentiment on the stock.
With the stock currently priced at Rs 2,879.10, GlaxoSmithKline Pharmaceuticals has seen a gain of 3.68% in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
